Get the Stockscreener App
115.71
1.54%
-1.81
Neurocrine Biosciences Inc stock is traded at $115.71, with a volume of 1.32M.
It is down -1.54% in the last 24 hours and up +21.44% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$117.52
Open:
$118.04
24h Volume:
1.32M
Relative Volume:
0.81
Market Cap:
$10.85B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
31.02
EPS:
3.73
Net Cash Flow:
$440.10M
1W Performance:
+5.50%
1M Performance:
+21.44%
6M Performance:
-7.98%
1Y Performance:
-17.15%
1-Day Range:
$115.66
$119.67
1-Week Range:
$108.35
$130.46
52-Week Range:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
115.71 | 10.85B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Neurocrine leans on singer Carnie Wilson for tardive dyskinesia push - Medical Marketing and Media
Neurocrine Reports Late Stage Data Of Crenessity - marketscreener.com
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgrou - PR Newswire
Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - MSN
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - Insider Monkey
Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday - Insider Monkey
Neurocrine Bio stock target raised at Needham following earnings By Investing.com - Investing.com South Africa
Neurocrine Bio stock target raised at Needham following earnings - Investing.com Australia
RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum By Investing.com - Investing.com South Africa
RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Receives Price Target Raise from C - GuruFocus
Neurocrine Biosciences’ Earnings Call Highlights Growth Amid Challenges - TipRanks
NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Bio - GuruFocus
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May - Longview News-Journal
Guggenheim Ups Price Target for Neurocrine (NBIX) Amid Ingrezza Sales Performance | NBIX Stock News - GuruFocus
Neurocrine Biosciences (NBIX) Price Target Raised by RBC Capital | NBIX Stock News - GuruFocus
Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Benzinga
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target By Investing.com - Investing.com India
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug - inkl
2 Pharma Stocks Staging Big Post-Earnings Moves - Schaeffer's Investment Research
NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Biosciences | NBIX Stock News - GuruFocus
Neurocrine Biosciences (NBIX) Target Price Raised by UBS Analyst | NBIX Stock News - GuruFocus
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong R - GuruFocus
BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating - marketscreener.com
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong Results | NBIX Stock News - GuruFocus
RBC Capital Increases Price Target for Neurocrine (NBIX) to $145 | NBIX Stock News - GuruFocus
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Seeking Alpha
UBS Elevates Neurocrine (NBIX) Price Target and Highlights Growth Prospects | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earni - GuruFocus
RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences (NBIX) Receives Price Target Raise from Canaccord Genuity | NBIX Stock News - GuruFocus
What 19 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga
Analyst Maintains Buy Rating on Neurocrine Biosciences (NBIX) with Raised Price Target | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Increased Following Strong Q1 Performance | NBIX Stock News - GuruFocus
S&P 500 Futures Drop in Premarket Trading; Neurocrine Biosciences, Regal Rexnord Lead - Barron's
Neurocrine Biosciences (NBIX) Price Target Increased by Canaccor - GuruFocus
Palantir, Ford, Tesla, Constellation Energy, Clorox, Hims & Hers, Neurocrine, AMD, and More Movers - Barron's
Neurocrine Biosciences (NBIX) Price Target Increased by Canaccord | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earnings Report | NBIX Stock News - GuruFocus
Palantir, Ford, Tesla, Clorox, Hims & Hers, Neurocrine, AMD, and More Market Movers - Barron's
Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... By GuruFocus - Investing.com Canada
Neurocrine Biosciences Reports Strong Q1 2025 Results - TipRanks
Neurocrine: Q1 Earnings Snapshot - The Washington Post
Earnings call transcript: Neurocrine Biosciences Q1 2025 results miss EPS expectations - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Surges 13% After Strong Q1 Results - GuruFocus
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.52%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):